No Data
No Data
Hybio Pharmaceutical Gets China Approval for Type 2 Diabetes Injection
hybio pharmaceutical (300199.SZ): received a large prepayment of over 45 million yuan from Hikma yesterday.
On October 14, Gelonhui reported that hybio pharmaceutical (300199.SZ) announced that the cooperation progress of Liralutide preparations with Hikma in the usa market is smooth. Yesterday, Hikma has received a large prepayment of more than RMB 45 million from Hikma, and the company will orderly advance the supply chain guarantee work according to the agreement of both parties. In addition, the independently developed Liralutide preparations of the company obtained Tentative approval from the FDA in the usa in June this year and initiated the application for listing and sales to the FDA at the end of September and obtained approval for acceptance. Please pay attention to the company's public information on this matter.
Revenues Not Telling The Story For Hybio Pharmaceutical Co., Ltd. (SZSE:300199) After Shares Rise 29%
Hybio Pharmaceutical (300199.SZ): Simvastatin active pharmaceutical ingredient obtained the US DMF filing number.
hybio pharmaceutical (300199.SZ) announced that the company has received confirmation from the Food and Drug Administration (FDA) of the United States...
hybio pharmaceutical (300199.SZ): Aseganotide injection approved for market
On September 18, Golonghui reported that Hybio Pharmaceutical (300199.SZ) recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration (Acceptance No.: CYHS2200468, CYHS2200469). The company's "Exenatide Injection" has obtained drug registration approval. Exenatide is a glucagon-like peptide-1 (GLP-1) analog, used to improve blood sugar control in patients with type 2 diabetes, suitable for patients who do not achieve adequate blood sugar control with metformin alone, sulfonylureas alone, or metformin in combination with sulfonylureas.
Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
No Data
No Data